An investigation published July 11, 2026 by journalist Ryan Cross finds US biotech firms are concealing research data, partnership details, and future plans in response to intensifying competition from Chinese companies. The defensive secrecy spans large pharmaceutical firms and startups, and it…
On July 11, 2026, journalist and investigator Ryan Cross published a detailed investigation finding that US biotech firms are increasingly concealing proprietary information and strategic plans. The reason, according to Cross, is intensifying competition with Chinese biotech companies. The report documents a departure from the more open practices that previously characterized the sector, and it describes widespread paranoia and defensive secrecy affecting both established pharmaceutical giants and emerging startups.
Trust, Cross reports, has become a scarce commodity in the industry, a fundamental change in how the sector views its competitive environment. US biotech companies are more cautious than they once were about sharing any information that could benefit Chinese competitors. The caution is not limited to the risk of losing a development race. It extends to concerns about intellectual property theft and reverse engineering. The immediate impact is heightened vigilance across the industry, while the long-term effects remain uncertain.
For a sector built on disclosure, the significance of the shift is difficult to overstate. Cross's investigation frames increased secrecy as a force that may slow scientific exchange, collaboration, and joint progress. Whether that slowdown occurs, and how large it might be, is not yet established.
Cross's investigation centers on three categories of deliberate concealment: research data, partnership details, and future directions. Research data reveals which biological hypotheses a company considers credible and which ones it has abandoned. Partnership details reveal who is working with whom, on what terms, and in which therapeutic areas. Future directions reveal where a company intends to spend its next round of capital or clinical development. Each category is a competitive asset.
The primary catalyst, according to Cross, is competitive pressure from Chinese biotech companies. The investigation does not treat that pressure as one factor among many. It is the analytical conclusion at the center of the report, even though the underlying material does not empirically measure the relationship between Chinese competition and US corporate secrecy.
The most notable finding is the breadth of the behavior. Cross reports paranoia across established pharmaceutical giants and emerging startups alike. For large companies, the burden of secrecy falls on broad portfolios, extensive partnership networks, and large flows of clinical data. For startups, the stakes are more existential: a single disclosure can alter a financing round or a licensing negotiation. Defensive secrecy, in other words, is not confined by company size.
The biotech industry's collaborative habits developed for structural reasons. Drug development is long, expensive, and uncertain, and most companies cannot move a candidate from discovery to market without partners. Collaborations, licensing deals, and open exchanges at conferences and in academic publications are the mechanisms through which those partners are found. A company that withholds its data may protect itself from competitors, but it also makes itself a less attractive collaborator.
Scientific validation depends on disclosure. Regulators cannot assess a clinical trial without methods and outcomes. Peer reviewers cannot judge a mechanism without the underlying data. Competing groups cannot build on a finding without knowing its exact parameters. Open exchange prevents duplication of failed experiments, which matters in a field where replication is expensive. When companies withhold information, they complicate not only their own partnerships but also the broader process of establishing what works and what does not.
For peptide science specifically, the dependence on shared knowledge is direct. Optimizing a peptide for clinical use, improving stability, solubility, bioavailability, and manufacturing yield, depends on accumulated knowledge about sequence-activity relationships and formulation science. That knowledge is distributed across companies, academics, and suppliers. It is not held by any single group. Defensive secrecy may protect a company's specific program, but it removes a portion of the shared substrate on which all peptide developers draw.
Biotech secrecy operates across a spectrum of instruments. Trade secret policies restrict what employees may disclose. Publication embargoes delay the release of results. Redacted contracts obscure financial and strategic terms. Material transfer agreements control who can access biological materials and what they can do with them. Each instrument is rational from a single company's perspective, and each adds friction to the surrounding scientific community.
The intellectual property system offers a choice that shapes those decisions. Patents require public disclosure of the invention in exchange for a limited monopoly. Trade secrets require no disclosure but can be lost through reverse engineering or independent discovery. For a peptide therapeutic, patent protection typically covers the amino acid sequence, the formulation, and the method of use. Once a patent publishes, competitors can read the sequence and design around it. Manufacturing know-how is different. Scale-up conditions, analytical methods, and impurity profiles are often kept as trade secrets because they are difficult to reverse engineer from a finished product.
The concern about reverse engineering, which Cross identifies as one driver of the paranoia, has a rational basis for peptides. Peptide sequences are relatively easy to determine once a drug is on the market or once a patent application publishes. What cannot be easily obtained is the record of what failed: which variants were unstable, which excipients caused aggregation, which manufacturing conditions produced impurities. That record is precisely the experience that gives a developer its competitive edge, and it is the information most vulnerable to defensive secrecy.
The competitive pressure Cross describes is not simply the normal pressure of a crowded market. A competitor that can move a candidate through clinical development quickly, or that can obtain a peptide sequence from a patent and develop an alternative manufacturing route, changes the value of early disclosure. Under those conditions, the cost of sharing information appears higher and the benefit of collaboration appears lower.
The fear extends beyond losing a race to a faster rival. Cross reports that US companies are worried about intellectual property theft and reverse engineering. For peptide drugs, this fear is specific rather than general. The sequence of a peptide is disclosed in patents and can be determined from a marketed product. What remains protected is the accumulated know-how: formulation decisions, manufacturing processes, analytical methods, and the record of failed approaches. That know-how is exactly what a competitor would want.
The result is a defensive posture that treats all information as potentially valuable to an adversary. A research presentation at a conference may reveal which analogs a company has prioritized. A partnership announcement may reveal a company's therapeutic focus. A clinical trial registration may reveal the dose, schedule, and patient population that matter most. Companies that once used these disclosures to attract collaborators now weigh the risk that the same information will be used against them.
The most immediate effect for peptide researchers is reduced access to proprietary data, partnership details, and emerging research directions. These are planning inputs. A researcher deciding whether to invest in a new delivery technology needs to know whether a company has already solved the formulation problem. A clinical investigator designing a trial needs the full safety profile of a candidate, not the portions a company chooses to present. When companies withhold information to block competitors, they also withhold it from collaborators, reviewers, and clinicians.
Clinical trial data transparency is a particular concern. Trial registration and results reporting are mandatory in many jurisdictions, but the depth and timing of disclosure can vary. Sponsors may delay interim analyses, restrict access to patient-level data, or decline to publish negative results. Cross's investigation does not document these outcomes, but the mechanism is plausible. Companies that fear competitive intelligence will scrutinize every disclosure for what it reveals about strategy, and late-stage peptide programs are not exempt from that scrutiny.
The supply chain could feel the effects indirectly. Peptide manufacturing often relies on specialized suppliers and contract development and manufacturing organizations. A sponsor that withholds process details from its manufacturing partner may receive less useful technical support. A supplier kept in the dark about clinical strategy may struggle to anticipate demand or customize raw materials. Trust, which Cross identifies as scarce, is also a logistical requirement. Contractual walls can replace trust, but they add friction, cost, and delay.
Cross's investigation is a work of journalism, not a quantitative study, and the limits of the available source material should be stated plainly. The facts reported here are based on a summary of Cross's investigation, and the full report's specific examples are not included. The account contains no quantitative evidence about the frequency or extent of the secrecy practices, no named companies, and no direct quotes from industry sources.
The claims about slowed scientific exchange are framed as possibilities, not observed outcomes. Cross reports that secrecy may slow collaboration and progress, but the investigation does not measure whether that has happened. Similarly, the characterization of Chinese competition as the primary catalyst is an analytical conclusion. It is consistent with the reported behavior, but it is not empirically measured. Domestic competition, regulatory pressure, and other factors could also contribute, and the report does not isolate one cause.
The word "widespread" is a qualitative judgment. Cross documents an attitude across the sector, but the source material provides no data on how many companies have changed their practices or how much information is now being withheld relative to earlier periods. That absence of evidence does not invalidate the reporting. It does set a limit on what can be concluded from it. What is documented is a departure in behavior and a set of stated concerns, not a measured decline in scientific exchange.
The largest open question is what specific examples of secrecy Cross details in the full report. Named examples would show whether the behavior is concentrated in certain therapeutic areas or certain development stages. They would also make it possible to assess whether the response to Chinese competition is proportionate to the actual risk. For peptide researchers, the relevant question is whether their field is being disproportionately affected.
A second open question is which companies or therapeutic areas are most affected. The source material does not name companies, so it cannot support conclusions about peptide companies specifically. Peptide-based drug development relies on collaborations, licensing, and published findings, and it depends on the same open exchange that Cross describes as under pressure.
Third, the investigation does not establish how increased secrecy might affect clinical…
Related reading: GLP-3s Show Promise in Phase 3 Weight Loss and Diabetes Trial, After Novo Unit Closure, AI Biotech Hires Expert for Parkinson's Stem Cell Review, GLP-1 Maker Eli Lilly Funded Clinical Trials at Chinese Military Sites, New once-daily pill outperforms oral semaglutide in diabetes trial.